• Login
View Item 
  • DASH Home
  • Harvard Kennedy School
  • HKS Center for International Development
  • View Item
  • DASH Home
  • Harvard Kennedy School
  • HKS Center for International Development
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Browse

All of DASH
  • Communities & Collections
  • By Issue Date
  • Author
  • Title
  • Keyword
  • FAS Department
This Collection
  • By Issue Date
  • Author
  • Title
  • Keyword

Submitters

  • Login
  • Quick submit
  • Waiver Generator

About

  • About DASH
  • DASH Stories
  • DASH FAQs
  • Accessibility
  • COVID-related Research
  • Terms of Use
  • Privacy Policy

Statistics

  • By Schools
  • By Collections
  • By Departments
  • By Items
  • By Country
  • By Authors

Advance Market Commitments for Vaccines Against Neglected Diseases: Estimating Costs and Effectiveness

 
Thumbnail
View/Open
127.pdf (165.8Kb)
Author
Berndt, Ernst R.
Glennerster, Rachel
Kremer, MichaelHARVARD
Jean, Lee
Levine, Ruth
Weizsäcker, Georg
Williams, HeidiHARVARD
Published Version
https://www.hks.harvard.edu/centers/cid/publications
Metadata
Show full item record
Citation
Berndt, Ernst R., Rachel Glennerster, Michael R. Kremer, Jean Lee, Ruth Levine, Georg Weizsäcker, and Heidi Williams. “Advance Market Commitments for Vaccines Against Neglected Diseases: Estimating Costs and Effectiveness." CID Working Paper Series 2006.127, Harvard University, Cambridge, MA, July 2006.
Abstract
The G8 is considering committing to purchase vaccines against diseases concentrated in low-income countries (if and when desirable vaccines are developed) as a way to spur research and development on vaccines for these diseases. Under such an “advance market commitment,” one or more sponsors would commit to a minimum price to be paid per person immunized for an eligible product, up to a certain number of individuals immunized. For additional purchases, the price would eventually drop to close to marginal cost. If no suitable product were developed, no payments would be made. We estimate the offer size which would make revenues similar to the revenues realized from investments in typical existing commercial pharmaceutical products, as well as the degree to which various model contracts and assumptions would affect the cost-effectiveness of such a commitment. We make adjustments for lower marketing costs under an advance market commitment and the risk that a developer may have to share the market with subsequent developers. We also show how this second risk could be reduced, and money saved, by introducing a superiority clause to a commitment. Under conservative assumptions, we document that a commitment comparable in value to sales earned by the average of a sample of recently launched commercial products (adjusted for lower marketing costs) would be a highly cost-effective way to address HIV/AIDS, malaria, and tuberculosis. Sensitivity analyses suggest most characteristics of a hypothetical vaccine would have little effect on the cost-effectiveness, but that the duration of protection conferred by a vaccine strongly affects potential cost-effectiveness. Readers can conduct their own sensitivity analyses employing a web-based spreadsheet tool.
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:42482341

Collections
  • HKS Center for International Development [541]

Contact administrator regarding this item (to report mistakes or request changes)

e: osc@harvard.edu

t: +1 (617) 495 4089

Creative Commons license‌Creative Commons Attribution 4.0 International License

Except where otherwise noted, this work is subject to a Creative Commons Attribution 4.0 International License, which allows anyone to share and adapt our material as long as proper attribution is given. For details and exceptions, see the Harvard Library Copyright Policy ©2022 Presidents and Fellows of Harvard College.

  • Follow us on Twitter
  • Contact
  • Harvard Library
  • Harvard University